Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms.
1/5 보강
[OBJECTIVE] To review the efficacy and safety of elinzanetant for the management of vasomotor symptoms (VMS) associated with menopause.
APA
Rowe JM, Coffman I, Barnes KN (2026). Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms.. The Annals of pharmacotherapy, 10600280261426643. https://doi.org/10.1177/10600280261426643
MLA
Rowe JM, et al.. "Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms.." The Annals of pharmacotherapy, 2026, pp. 10600280261426643.
PMID
41869786
Abstract
[OBJECTIVE] To review the efficacy and safety of elinzanetant for the management of vasomotor symptoms (VMS) associated with menopause.
[DATA SOURCES] Literature was identified using PubMed (1966 to January 2026), EMBASE (1973 to January 2026), and clinicaltrials.gov. Search terms included elinzanetant, VMS, and menopause, limiting trials to those published in English.
[STUDY SELECTION AND DATA EXTRACTION] Articles selected for inclusion included trials evaluating elinzanetant for the treatment of VMS.
[DATA SYNTHESIS] Elinzanetant was evaluated for reduction in frequency and severity of moderate-to-severe VMS associated with menopause in 3 phase 3 trials (OASIS 1, 2, and 3) and 1 phase 3 trial in patients receiving endocrine therapy for breast cancer (OASIS 4). All studies showed significant improvements in symptom frequency at week 12 compared to placebo ( < .001). Improvement in sleep disturbances and quality of life was also significant in OASIS 1, 2, and 4. Elinzanetant was well-tolerated, with headache, fatigue, dizziness, somnolence, abdominal pain, and rash reported as the most frequent drug-associated adverse effects.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Elinzanetant is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for moderate-to-severe VMS associated with menopause. Elinzanetant offers a nonhormonal treatment option with favorable tolerability, representing a promising alternative for patients who cannot or prefer not to use hormonal therapy.
[CONCLUSION] The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.
[DATA SOURCES] Literature was identified using PubMed (1966 to January 2026), EMBASE (1973 to January 2026), and clinicaltrials.gov. Search terms included elinzanetant, VMS, and menopause, limiting trials to those published in English.
[STUDY SELECTION AND DATA EXTRACTION] Articles selected for inclusion included trials evaluating elinzanetant for the treatment of VMS.
[DATA SYNTHESIS] Elinzanetant was evaluated for reduction in frequency and severity of moderate-to-severe VMS associated with menopause in 3 phase 3 trials (OASIS 1, 2, and 3) and 1 phase 3 trial in patients receiving endocrine therapy for breast cancer (OASIS 4). All studies showed significant improvements in symptom frequency at week 12 compared to placebo ( < .001). Improvement in sleep disturbances and quality of life was also significant in OASIS 1, 2, and 4. Elinzanetant was well-tolerated, with headache, fatigue, dizziness, somnolence, abdominal pain, and rash reported as the most frequent drug-associated adverse effects.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Elinzanetant is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for moderate-to-severe VMS associated with menopause. Elinzanetant offers a nonhormonal treatment option with favorable tolerability, representing a promising alternative for patients who cannot or prefer not to use hormonal therapy.
[CONCLUSION] The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.